Administer the Injection Pinch the fat to ensure youre only penetrating SQ tissue
Verified documentation
Higher NAD+ supports the cellular processes behind energy, repair, and metabolic resilience
You should contact your GP, call NHS 111, or seek urgent medical advice if you are currently using unlicensed peptides and experience any of the following: Severe or persistent nausea, vomiting, or abdominal pain Signs of infection at an injection site (redness, swelling, warmth, discharge) Unexplained changes in heart rate or palpitations Symptoms of an allergic reaction (rash, swelling, difficulty breathing) Persistent right upper quadrant pain, fever, or jaundice (which may indicate gallbladder problems) Significant unintentional weight loss or fatigue Call 999 or go to your nearest emergency department if symptoms are severe or rapidly worsening
What Patients Evaluating AOD 9604 Typically Report Timeline to first changes: Most published protocols note 4 to 6 weeks before body composition changes become measurable Areas of change: Visceral and subcutaneous fat reduction, with particular effect reported in the abdominal region in some subjects Energy and recovery: Some participants in clinical and investigational settings report improved energy and exercise recovery, though this is not a primary mechanism of the peptide What it is not: AOD 9604 does not cause rapid dramatic weight loss the way GLP-1 medications can in the first few months
